Results 21 to 30 of about 766 (168)

Outcomes of front-line tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a real-world scenario [PDF]

Journal of Hematology & Oncology
Tagraxofusp (TAG), a CD123-directed protein-drug conjugate, is approved in front-line and relapsed/refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Jan C. Schroeder, Philipp Faustmann, Snjezana Janjetovic, Anna Ossami Saidy, Hanna K. Zieger, Giuliano Filippini Velazquez, Thomas Melchardt, David Baden, Hristo Boyadzhiev, Tim Sauer, Christoph Schliemann, Jan-Henrik Mikesch, Niklas Gebauer, Susanne von Kroge, Paul J. Bröckelmann, Friederike Hildebrand, Veit Bücklein, Rebecca Wurm-Kuczera, Ulrich Keller, Thomas Pabst, Maher Hanoun, Claudia Lengerke, Evgenii Shumilov, Georg Lenz, Ulrike Bacher, Philipp Berning   +25 more
doaj   +2 more sources

Tagraxofusp

Reactions Weekly, 2022
core   +6 more sources

Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm

Journal of Clinical Oncology, 2022
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or ...
Naveen Pemmaraju, Kendra L. Sweet, Anthony S. Stein, Eunice S. Wang, David A. Rizzieri, Sumithira Vasu, Todd L. Rosenblat, Christopher L. Brooks, Nassir Habboubi, Tariq I. Mughal, Hagop Kantarjian, Marina Konopleva, Andrew A. Lane   +12 more
openaire   +3 more sources

Blastic plasmacytoid dendritic cell neoplasm: a Swiss case series of a very rare disease and a structured review of the literature

Swiss Medical Weekly
INTRODUCTION: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease, with unique diagnostic challenges and often dismal outcome. There are no widely accepted treatment guidelines available.
Ramona Meier-Lienhard, Cosima Suter, Thomas Pabst, Felicitas Hitz, Jakob R. Passweg, Olivier Spertini, Nathan Cantoni, Daniel Betticher, Lucas Simeon, Michael Medinger, Stefanie Hayoz, Adrian Schmidt   +11 more
doaj   +2 more sources

Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm [PDF]

Leukemia Research Reports
Presented here is the case of a 68-year-old woman with blastic plasmacytoid dendritic cell neoplasm (BPDCN) treated with tagraxofusp (TAG) maintenance therapy post-allogeneic hematopoietic stem cell transplantation (allo-HCT).
Qaiser Bashir, Marina Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar Qazilbash, Naveen Pemmaraju   +13 more
doaj   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm: A Comprehensive Review of the Disease, Central Nervous System Presentations, and Treatment Strategies

Cells
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy with poor outcomes. The World Health Organization (WHO) redefined BDCN as a distinct disease entity in 2016. BPDCN arises from plasmacytoid dendritic cells,
Shefali Mehra, Justin Taylor
doaj   +2 more sources

Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting [PDF]

Journal of Immunotherapy and Precision Oncology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically aggressive hematologic malignancy with limited treatment options.
Prajwal Dhakal, Mario Sy, Grerk Sutamtewagul, Eric Mou, Nanmeng Yu, Naveen Pemmaraju   +5 more
doaj   +2 more sources

Case Report: A rare RUNX1 rearrangement resulting from t(8;21)(p12;q22) in acute myeloid leukemia with plasmacytoid dendritic cell expansion [PDF]

Frontiers in Oncology
In recent years, acute myeloid leukemia with plasmacytoid dendritic cell expansion (pDC-AML) has been recognized as a rare provisional subtype of AML, comprising approximately 3–5% of all reported cases and associated with a poorer clinical outcome ...
Jinying Gong, Jinying Gong, Jialong Liu, Lisha Lu, Lisha Lu, Jiru Wei, Xue Wu, Junyan Zou, Yuan Feng, Guoqing Zhu, Guoqing Zhu, Jing Han   +11 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm presenting as a scalp hematoma [PDF]

JAAD Case Reports
Eduardo A. Michelen-Gómez, MD, Karina Cancel-Artau, MD, Cristina P. Gerena-Maldonado, MD, Iancarlos Jiménez-Sacarello, MD, María Rivera-Rolón, MD, Julio E. Sánchez-Pont, MD, Rafael F. Martín-García, MD   +6 more
doaj   +2 more sources

Tagraxofusp

Reactions Weekly, 2023
openaire   +2 more sources